Clinical Trials
NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today...
Clinical Trials
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE)...
Clinical Trials
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
Plexxikon Inc. announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor,...
Clinical Trials
Sanofi-aventis Reports Top-line Results from Phase III Study with BSI-201 in Metastatic Triple-Negative Breast Cancer
Sanofi-aventis and its subsidiary, BiPar Sciences, announced that a randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did...
Clinical Trials
Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction of Submental Fat
Bayer HealthCare’s dermatology business Intendis and KYTHERA Biopharmaceuticals, Inc. announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent,...
Clinical Trials
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety...
Clinical Trials
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.